{"name":"Avanir Pharmaceuticals","slug":"avanir","ticker":"AVNR","exchange":"NASDAQ","domain":"avanir.com","description":"Avanir Pharmaceuticals is a specialty neuroscience pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company's top drugs include Nuedexta, which is used to treat pseudobulbar affect (PBA), and Zenvia, which is used to treat postherpetic neuralgia (PHN). Avanir has a strong presence in the CNS market and continues to invest in research and development to expand its product portfolio.","hq":"Aliso Viejo, CA","founded":0,"employees":"","ceo":"Nick Kozauer","sector":"Specialty Neuroscience Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Subsidiary (Otsuka)","metrics":{"revenue":420000000,"revenueGrowth":52.6,"grossMargin":0,"rdSpend":44004000,"netIncome":-50436000,"cash":306983000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2014"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Nuedexta patent cliff ($100M at risk)","drug":"Nuedexta","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Neurodex","genericName":"Neurodex","slug":"neurodex","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Neurodex","genericName":"Neurodex","slug":"neurodex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Avanir Pharmaceuticals Announces FDA Approval of Zenvia for the Management of Postherpetic Neuralgia","summary":"Avanir Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Zenvia for the management of postherpetic neuralgia (PHN).","drugName":"Zenvia","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Avanir Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Avanir Pharmaceuticals reported its third quarter 2023 financial results, with net sales of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Avanir Pharmaceuticals Announces Collaboration with the Michael J. Fox Foundation for Parkinson's Research","summary":"Avanir Pharmaceuticals announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to develop a new treatment for Parkinson's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQemQtX3BOMWQ3eHBlRFhoMEhkOWlxdXZWTnF0b1BJc3NUN2pNbmVyWFhmRW1Ec2ZpU1YtMU1zQ0owb2c2TWdOUHBYTGlRaF9qdW1lTk5ENGFyWmYxVXhFTDE0R3BQYVUxdHRIcDVNOVZmcURPVDFHVWd3V3BhMUs2YnhFR3ZNaDBiLVR5WHBackRZSXVSN1lzUGhXSEdQRTg3Sjh3?oc=5","date":"2016-05-10","type":"pipeline","source":"Fierce Pharma","summary":"Want a celeb endorser? 'Minus one, multiply by 20,' expert says - Fierce Pharma","headline":"Want a celeb endorser? 'Minus one, multiply by 20,' expert says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1nY2lPXzAtdnRQNjRjWnlwSkg1aUsyN0t5aFZXSklFNDctNURsS2JJZlR6b2RnTC1rOVhWVGQwN0VWZkxpdGhhSDRSdGdkVEI0bkxENHlnMkF4OFlqS3JTdHJpTGd4d3FsU1ZCVjNiUDJ5V1R5dDhpSnJR?oc=5","date":"2015-01-12","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 10 Wall Street Winners of 2014 - Genetic Engineering and Biotechnology News","headline":"Top 10 Wall Street Winners of 2014","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5jcmxRYl82WVNVVllDUl8yZGNwY0Mxcjl3eTBiTHhqZ1dmTk1aaVVpZXRycG1KMWVwZ0VCbk5sMGEyUDA5c01PTm5hMEJRcDJYc2RjejM4alB6anhTVXRsZjcyQ21FV21KSUV0Nl8yWEotLWhTVV9KMNIBfkFVX3lxTE1wSm9oYmN5Mkl6YWhpbVQyLWRjb0dqWDBUbV9udU1Bc29GV2NuVGdLcjFaOTFBTENTT1hFWkRPdTRLSEdWYjVfT1dyZ2J2cGlMeHRyZGs5TTFwcWlmc2Yya2JtWV94b1k3WU5UOTNYRWlNdFZMZERGMzk0OFY1QQ?oc=5","date":"2014-12-02","type":"deal","source":"CBS News","summary":"Japanese drugmaker buys Avanir for $3.5B - CBS News","headline":"Japanese drugmaker buys Avanir for $3.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNVVkwUUlDdy1JMlR5RlFJNnlseFUwUXNQM0huRXF3NlYzNWtaVVp4VzN2b01UY3dJVXRTa0JPN284RHhrdnR1RkxMLTRUVHVzNldJWEdvVDU2QzM4V2dZTVEwaFhneFlRSUVXLVd3OG9KTlRnYlFMQ3I4TnVHSERnWmw4bmF3bGZPYklSeWR6allpUVZxdml5TW5GQVcyS2xFNFJpZmhIY2UzVktzR2pBT1RTOHEwYUxFSWF3RjMzNGVyQ01MSmc?oc=5","date":"2012-08-08","type":"earnings","source":"thestreet.com","summary":"Avanir Pharmaceuticals' CEO Discusses F3Q12 Results – Earnings Call Transcript - thestreet.com","headline":"Avanir Pharmaceuticals' CEO Discusses F3Q12 Results – Earnings Call Transcript","sentiment":"neutral"}],"patents":[{"drugName":"Nuedexta","drugSlug":"dextromethorphan-and-quinidine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Pfizer","Eli Lilly"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":115029000,"revenuePeriod":"2014-09-30","revenueHistory":[{"value":115029000,"period":"2014-09-30"},{"value":75365884,"period":"2013-09-30"},{"value":75366000,"period":"2013-09-30"},{"value":41275073,"period":"2012-09-30"},{"value":41275000,"period":"2012-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":44004000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-50436000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":306983000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}